1h Free Analyst Time
The dravet syndrome treatment market is forecasted to grow by USD 727.9 million during 2023-2028, accelerating at a CAGR of 10.87% during the forecast period. The report on the dravet syndrome treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growth in special regulatory designations, increasing new product launches, and advancements in genetic therapeutics for DS treatment.
The dravet syndrome treatment market is segmented as below:
By Product
- SGDs
- TGDs
- FGDs
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- E-commerce
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the dravet syndrome treatment market covers the following areas:
- Dravet syndrome treatment market sizing
- Dravet syndrome treatment market forecast
- Dravet syndrome treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. IT presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global dravet syndrome treatment market: AbbVie Inc., BIOCODEX SAS, Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., UCB SA, Viatris Inc., Xenon Pharmaceuticals Inc., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increased use of new-generation drugs."
According to the report, one of the major drivers for this market is the growth in special regulatory designations.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- BIOCODEX SAS
- Encoded Therapeutics Inc.
- Epygenix Therapeutics Inc.
- H Lundbeck AS
- Jazz Pharmaceuticals Plc
- Johnson and Johnson Services Inc.
- Lupin Ltd.
- PTC Therapeutics Inc.
- Stoke Therapeutics Inc.
- Sun Pharmaceutical Industries Ltd.
- Supernus Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Thermo Fisher Scientific Inc.
- UCB SA
- Viatris Inc.
- Xenon Pharmaceuticals Inc.
- Zydus Lifesciences Ltd.
